TLR4 and melanoma: Several studies have also shown a beneficial effect of TLR4 agonists in vivo to promote anti-tumor responses (40), with a recent publication highlighting the combination of PD-1 blockade and TLR4 stimulation with brucella lumazine synthase to increase the immune infiltrate and anti-tumor effects in B16 melanoma pre-clinical models (41).